828 Views | 1,121 Downloads
Corresponding authors at: Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. E-mail addresses: duo.li@usz.ch (D. Li), Roberto.speck@usz.ch (R.F. Speck).
DL designed, conducted and analyzed all experiments.
ES, AA, M-A.R, SI, C-N.K, BK, O-T.K assisted in some experiment.
DL, AA and RS wrote the paper.
We thank D. Boden (Tibotec, Belgium) for providing pLen-EF1α-GFP and the NIH AIDS Reagent Program for providing Raltegravir (Cat # 11680; from Merck & Company).
We are grateful to N.R. Landau, O.T. Fackler H.M. Baldauf, V. Vongrad, Y.L. Kok and A. Scherrer for advice.
The study was supported by the OPO-Foundation and the clinical research focus program “Human Hemato-Lymphatic Diseases” of the University of Zürich (10/2012-10/2015).
RFS is supported by the SNF (SSAJRP; IZLSZ3_149100/1).
This work was partially supported by US National Institute of Health grant GM104198 (B.K.).
© 2015 The Authors. Published by Elsevier B.V.